Kiniksa Pharmaceuticals International, plc (KNSA) stock
KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.11+0.88 (+0.93%)
Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –
Kiniksa Pharmaceuticals International r&d expenses
Research and development expenses are spending on new products and technology.
Kiniksa Pharmaceuticals International's R&D Expenses for the twelve months ending Sep 30, 2026 was $135.77M, up 39.3% year over year. For fiscal 2025 it was $96.85M, down 13.2% from the year before. The highest annual figure on record is $135.00M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $96.85M | -13.2% |
| FY2024 | Dec 31, 2024 | $111.62M | +46.7% |
| FY2023 | Dec 31, 2023 | $76.10M | +16.2% |
| FY2022 | Dec 31, 2022 | $65.49M | -34.0% |
| FY2021 | Dec 31, 2021 | $99.30M | -11.4% |
| FY2020 | Dec 31, 2020 | $112.04M | -17.0% |
| FY2019 | Dec 31, 2019 | $135.00M | +55.9% |
| FY2018 | Dec 31, 2018 | $86.60M | +53.7% |
| FY2017 | Dec 31, 2017 | $56.36M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $32.79M | +35.7% |
| Q2 FY2026 | Jun 30, 2026 | $40.90M | +118.1% |
| Q1 FY2026 | Mar 31, 2026 | $27.48M | +42.2% |
| Q4 FY2025 | Dec 31, 2025 | $34.61M | -1.7% |
| Q3 FY2025 | Sep 30, 2025 | $24.17M | -7.3% |
| Q2 FY2025 | Jun 30, 2025 | $18.75M | -21.9% |
| Q1 FY2025 | Mar 31, 2025 | $19.33M | -26.6% |
| Q4 FY2024 | Dec 31, 2024 | $35.22M | +75.6% |
| Q3 FY2024 | Sep 30, 2024 | $26.06M | +52.3% |
| Q2 FY2024 | Jun 30, 2024 | $24.02M | +1.1% |
| Q1 FY2024 | Mar 31, 2024 | $26.33M | +73.6% |
| Q4 FY2023 | Dec 31, 2023 | $20.05M | +39.3% |
| Q3 FY2023 | Sep 30, 2023 | $17.11M | +3.8% |
| Q2 FY2023 | Jun 30, 2023 | $23.77M | +72.2% |
| Q1 FY2023 | Mar 31, 2023 | $15.17M | -27.1% |
| Q4 FY2022 | Dec 31, 2022 | $14.39M | -47.5% |
| Q3 FY2022 | Sep 30, 2022 | $16.49M | -14.3% |
| Q2 FY2022 | Jun 30, 2022 | $13.80M | -42.4% |
| Q1 FY2022 | Mar 31, 2022 | $20.82M | -27.4% |
| Q4 FY2021 | Dec 31, 2021 | $27.43M | -26.6% |
| Q3 FY2021 | Sep 30, 2021 | $19.24M | -38.8% |
| Q2 FY2021 | Jun 30, 2021 | $23.95M | +7.3% |
| Q1 FY2021 | Mar 31, 2021 | $28.68M | +37.2% |
| Q4 FY2020 | Dec 31, 2020 | $37.40M | +63.4% |
| Q3 FY2020 | Sep 30, 2020 | $31.42M | +42.7% |
| Q2 FY2020 | Jun 30, 2020 | $22.32M | -27.6% |
| Q1 FY2020 | Mar 31, 2020 | $20.90M | -64.7% |
| Q4 FY2019 | Dec 31, 2019 | $22.89M | -36.6% |
| Q3 FY2019 | Sep 30, 2019 | $22.01M | +6.6% |
| Q2 FY2019 | Jun 30, 2019 | $30.85M | +79.3% |
| Q1 FY2019 | Mar 31, 2019 | $59.25M | +369.1% |
| Q4 FY2018 | Dec 31, 2018 | $36.12M | +20.7% |
| Q3 FY2018 | Sep 30, 2018 | $20.64M | +47.4% |
| Q2 FY2018 | Jun 30, 2018 | $17.20M | +85.5% |
| Q1 FY2018 | Mar 31, 2018 | $12.63M | – |
| Q4 FY2017 | Dec 31, 2017 | $29.93M | – |
| Q3 FY2017 | Sep 30, 2017 | $14.01M | – |
| Q2 FY2017 | Jun 30, 2017 | $9.27M | – |
See a number that looks wrong?